CG Oncology to Present First Phase 2 Trial Results for NMIBC Therapy at AUA Meeting
CGON has more than doubled off its 52-week low of $23.32.
Summary
CG Oncology announced its participation in the American Urological Association (AUA) 2026 Annual Meeting, where it will present the first results from its CORE-008 Cohort CX Phase 2 Trial. This trial evaluates an intravesical combination therapy for high-risk BCG-exposed and BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients. For a late-stage clinical biopharmaceutical company, the presentation of initial Phase 2 data at a major industry conference is a significant event, as it provides the first public look at the efficacy and safety profile of a key pipeline asset. Traders will be closely watching for the outcome of these presentations, scheduled for May 15-16, 2026, as they could materially impact the company's valuation and future development path.
At the time of this announcement, CGON was trading at $69.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.9B. The 52-week trading range was $23.32 to $73.56. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.